Skip to main content
. Author manuscript; available in PMC: 2019 Sep 5.
Published in final edited form as: Leukemia. 2019 Mar 12;33(9):2208–2226. doi: 10.1038/s41375-019-0414-z

Figure 8. Enhanced immune function of heteroclitic BCMA72–80 peptide-specific memory CTL in combination with anti-LAG3 or anti-OX40.

Figure 8

Figure 8

Figure 8

Anti-myeloma activities were investigated in treatment of hBCMA72–80 CTL with anti-LAG3 or anti-OX40. Fig. 8A. The CD107a degranulation by CD45RO+ memory cells or CD45RO− non-memory cells in hBCMA72–80 CTL, untreated or treated, against U266 or McCAR cells. Fig. 8B. The CD107a degranulation by central memory (CD45RO+CCR7+) CD3+CD8+ T cells in hBCMA72–80 CTL, untreated or treated, against U266 or McCAR cells. Fig. 8C. The percent increase of CD107a+ cells induced by hBCMA72–80 CTL generated from three different HLA-A2+ donors (N=3), untreated or treated with anti-OX40, against U266, McCAR or RPMI cells.